Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] EXAMINE: targeting risk and treatment in diabetes

We read the report by Faiez Zannad and colleagues1 with great interest, especially in the context of the SAVOR-TIMI 53 study.2 Both analyses found significant cardiovascular event rates only in patients with high concentrations of N-terminal pro brain natriuretic peptide (NT-proBNP); adverse events in patients with low concentrations of NT-proBNP were negligible. This result is in accordance with previous findings,3–5 which proves that NT-proBNP is currently the best marker for cardiovascular-risk stratification in patients with diabetes.